Vsx2 Dependent Regulation of Retinal Progenitor Cell Properties

视网膜祖细胞特性的 Vsx2 依赖性调节

基本信息

  • 批准号:
    10667540
  • 负责人:
  • 金额:
    $ 54.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-08-01 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

A fundamental question in organ formation is how the constituent tissues achieve their correct sizes and cytoarchitectures. Defects in a single tissue can affect the formation of an entire organ and a classic example of this is the eye, where disruptions in retinal histogenesis can cause microphthalmia, a severe ocular anomaly characterized by small, poorly formed eyes and congenital blindness. Mutations in the Visual System Homeobox 2 (Vsx2) gene cause microphthalmia. A definitive marker of retinal specification, Vsx2 functions in retinal progenitor cells to define tissue identity. Concurrently, Vsx2 is required for progenitor proliferation and several aspects of the neurogenic program including the timing of neurogenesis onset (neurogenic timing), and the fate specification of bipolar cells. Two gaps in our understanding are the mechanistic interconnectedness of the progenitor properties regulated by Vsx2 and whether progenitors change in how they utilize Vsx2 over the course of histogenesis. To address these gaps, we generated two new Vsx2 alleles in mice, one with a knock-in reporter/knock-out configuration and the other for conditional gene inactivation. In the first two aims, we will characterize the retinal phenotypes of these mutant alleles and determine how they compare to phenotypes caused by a natural null allele and two missense alleles that correspond to disease-causing mutations in humans. Conditional gene inactivation will be done with tamoxifen-inducible Cre/lox recombination to determine the temporal windows of Vsx2 utilization in progenitors and test the hypothesis that Vsx2’s control of retinal identity, neurogenic timing, and proliferation are separable. We also predict that additional roles in the balanced production of cells in each retinal cell class (neurogenic output) will be unmasked by temporal inactivation after the start of neurogenesis. In the third aim, we test the hypothesis that retinal identity control shifts from a Vsx2-dependent to independent state that is epigenetically defined for some of the earlier targets. In the fourth aim, we will incorporate an ex vivo culture paradigm to test candidate genes identified in the previous aims for their functional significance in promoting or interfering with retinal development. Completion of these studies will provide new insights into how Vsx2 orchestrates retinal progenitor properties and how retinal progenitors drive retinal histogenesis, an essential component of eye organogenesis.
器官形成中的一个基本问题是组成组织如何达到其正确的大小和 细胞结构。单个组织中的缺陷会影响整个器官和经典组织的形成 这方面的例子是眼睛,视网膜组织发生的中断会导致小眼炎,一种严重的 眼畸形以小而畸形的眼睛和先天失明为特征的眼畸形基因突变 视觉系统同源盒2(Vsx2)基因可引起小眼球。视网膜的明确标志 规范中,Vsx2在视网膜祖细胞中发挥功能,以定义组织特性。同时,Vsx2是 祖细胞增殖所需的时间和神经发生计划的几个方面,包括时间 神经发生的开始(神经发生的时间),以及双极细胞的命运指定。我们的两个差距 理解是受Vsx2调控的前体属性的机械性互连 以及祖细胞在组织发生过程中是否改变了他们利用Vsx2的方式。致信地址 在这些缺口中,我们在小鼠身上产生了两个新的Vsx2等位基因,其中一个带有敲入报告/敲除 配置和另一个用于条件基因失活。在前两个目标中,我们将描述 这些突变等位基因的视网膜表型,并确定它们与由 与人类致病突变相对应的自然零等位基因和两个错义等位基因。 条件基因失活将通过三苯氧胺诱导的Cre/lox重组来确定 Vsx2在祖细胞中利用的时间窗,并检验Vsx2的S控制的假说 视网膜的同一性、神经源性的时间和增殖是可分离的。我们还预测,在 每一类视网膜细胞的平衡生产(神经源性输出)将被 神经发生开始后的暂时性失活。在第三个目标中,我们测试了视网膜 身份控制从Vsx2依赖状态转变为独立状态,这是从表观上为某些人定义的 早些时候的目标。在第四个目标中,我们将结合体外培养范式来测试候选人 在先前的目的中确定的基因在促进或干扰 视网膜发育。这些研究的完成将为Vsx2如何协调提供新的见解 视网膜前体细胞的特性以及视网膜前体细胞如何驱动视网膜组织发生 眼睛器官发生的组成部分。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Expression of the cyclin-dependent kinase inhibitor p27Kip1 by developing retinal pigment epithelium.
视网膜色素上皮细胞中细胞周期蛋白依赖性激酶抑制剂 p27Kip1 的表达。
  • DOI:
    10.1016/s1567-133x(03)00120-0
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Defoe,DennisM;Levine,EdwardM
  • 通讯作者:
    Levine,EdwardM
Differential Expression of NF2 in Neuroepithelial Compartments Is Necessary for Mammalian Eye Development.
  • DOI:
    10.1016/j.devcel.2017.11.011
  • 发表时间:
    2018-01-08
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    Moon KH;Kim HT;Lee D;Rao MB;Levine EM;Lim DS;Kim JW
  • 通讯作者:
    Kim JW
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD M LEVINE其他文献

EDWARD M LEVINE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD M LEVINE', 18)}}的其他基金

Neurogenic potential of murine Müller glia following retinal injury and conditional inactivation of p27Kip1
视网膜损伤和 p27Kip1 条件失活后小鼠 Müller 胶质细胞的神经源性潜力
  • 批准号:
    10354817
  • 财政年份:
    2022
  • 资助金额:
    $ 54.31万
  • 项目类别:
Neurogenic potential of murine Müller glia following retinal injury and conditional inactivation of p27Kip1
视网膜损伤和 p27Kip1 条件失活后小鼠 Müller 胶质细胞的神经源性潜力
  • 批准号:
    10541894
  • 财政年份:
    2022
  • 资助金额:
    $ 54.31万
  • 项目类别:
Novel Activators of Regeneration in Muller glia
穆勒胶质细胞再生的新型激活剂
  • 批准号:
    9340183
  • 财政年份:
    2016
  • 资助金额:
    $ 54.31万
  • 项目类别:
New Mouse Models of Microphthamia
新的小口症小鼠模型
  • 批准号:
    7296420
  • 财政年份:
    2007
  • 资助金额:
    $ 54.31万
  • 项目类别:
New Mouse Models of Microphthamia
新的小口症小鼠模型
  • 批准号:
    7475038
  • 财政年份:
    2007
  • 资助金额:
    $ 54.31万
  • 项目类别:
Histomics
组织学
  • 批准号:
    8937284
  • 财政年份:
    2005
  • 资助金额:
    $ 54.31万
  • 项目类别:
Histomics
组织学
  • 批准号:
    9123600
  • 财政年份:
    2005
  • 资助金额:
    $ 54.31万
  • 项目类别:
Role of Chx10 in embryonic Retinal Progenitor Cells
Chx10 在胚胎视网膜祖细胞中的作用
  • 批准号:
    8204529
  • 财政年份:
    2003
  • 资助金额:
    $ 54.31万
  • 项目类别:
Role of Chx10 in embryonic Retinal Progenitor Cells
Chx10 在胚胎视网膜祖细胞中的作用
  • 批准号:
    7994768
  • 财政年份:
    2003
  • 资助金额:
    $ 54.31万
  • 项目类别:
Vsx2 Dependent Regulation of Retinal Progenitor Cell Properties
视网膜祖细胞特性的 Vsx2 依赖性调节
  • 批准号:
    10299449
  • 财政年份:
    2003
  • 资助金额:
    $ 54.31万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了